Abstract: Certain azapirone compounds and their pharmaceutically acceptable salts are useful in the treatment of substance addiction.

Abstract: The present invention provides an anti cancer treatment which has an improved stability and does not produce acrolein. The invention includes dichlorodiethyl phosphoramide drugs including, for example, the cyclohexylamine salt phosphoramide mustard and isophosphoramide mustard and mixtures thereof, which have been entrapped by liposomes. Preferably the liposomes contain sphingomyelin and cholesterol.

Abstract: A prophylactic and remedial preparation for a disease attendant on hyperglycemia, a preparation for depressing the rise in blood sugar, and a wholesome food separately include, as an active ingredient, at least one component selected from the group consisting of L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose and D-xylulose.

Abstract: A method for promoting wound healing involving initiating and accelerating wound repair and tissue regeneration in an animal by systemic administration of a bioactive polysaccharide derived from aloe vera plant.

Abstract: The present invention relates to a method for enhancing white blood cell functioning and metabolism on a mucosal surface of a mammal. The present invention also relates to a method for treating or preventing a condition in a mammal caused by the presence of a disease-causing agent on a mucosal surface or a cutaneous surface wherein the disease-causing agent can be diminished by the actions of the white blood cells. The present invention yet also relates to a method for healing a wound of a mucosal or cutaneous surface. The present invention also relates to compositions for use in such methods.

Abstract: A solid free flowing bird aversion compound comprising a bird aversion agent in an amount of from 10 to 80%, preferably from 30-75%, by weight of a total weight of the compound; and an inorganic or organic carrier in an amount of from 20 to 90%, preferably from 25-70%, by weight of a total weight of the compound. A bird aversion solution which is lighter than water comprising a bird aversion agent in an amount of from 5 to 50% by weight of a total weight of the solution; a terpene hydrocarbon and oxygenated derivative thereof in an amount of from 10 to 50% by weight of a total weight of the solution; and alkylesters selected from the group consisting of saturated fatty acids having from 4-20 carbon atoms and unsaturated fatty acids having from 10-18 carbon atoms esterified with an alcohol having from 1-8 carbon atoms in an amount of from 10 to 50% by weight of a total weight of the solution.

Abstract: Methods for treating various autoimmune diseases and for providing immunorestoration, by administering, to a subject in need thereof, an effective amount of a composition having, as active ingredient, one or more rhamnolipids of formula (I) ##STR1## wherein R.sup.1 is H or .alpha.-L-rhamnopyranosyl;R.sup.2 is H or --CH(R.sup.4)--CH.sub.2 --COOH;R.sup.3 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl andR.sup.4 is (C.sub.5 -C.sub.20)-saturated, mono or polyunsaturated hydrocarbyl;are provided.

Abstract: A ready-to-eat cereal product contains a substantial portion of typical cereal grain component, such as bran, wheat and the like, together with a therapeutic quantity of psyllium. The quantity of psyllium is sufficient to reduce the cholesterol level of humans and animals when part of the diet. The psyllium may be added as an intermediate psyllium product prepared by directly expanding psyllium husks, either by itself or together with minor amounts of other ingredients. The psyllium intermediate is preferably added during the process for making the final cereal product after the typical cereal grain components have been totally or partially cooked.

Abstract: Composition for the treatment of gingivitis and other afflictions of the oral cavity, as well as for the reduction of dental plaque. These are in the form of gels, solutions or similar forms which comprise a therapeutically active agent in a polymeric carrier which contains a solvent. The nature of the preparation is such that when these are applied to an aqueous environment of the oral cavity, the polymer and the active agent precipitate and form a coating.

Abstract: This invention involves new compositions and methods of use and delivery of amorphous calcium compounds such as: amorphous calcium phosphate (ACP), amorphous calcium phosphate fluoride (ACPF), amorphous calcium carbonate phosphate (ACCP), amorphous calcium carbonate phosphate fluoride (ACCPF), and amorphous calcium fluoride (ACF) for use in remineralizing and fluoridating teeth. These amorphous compounds or solutions which form the amorphous compounds, when applied either onto or into dental tissue prevent and/or repair dental weaknesses such as dental caries, exposed roots and dentin sensitivity. The compounds have the highest solubilities, fastest formation rates and fastest conversion rates (to apatite) among all the calcium phosphates under physiological conditions. Moreover, in the presence to fluoride the amorphous compound convert rapidly to fluoride containing apatite.

Abstract: Autoimmune diseases are controlled by the administration of non-methylene interrupted fatty acids of the formula ##STR1## in which R is alkyl or alkenyl. A preferred compound within the scope of this formula is 5,11,14-eicosatrienoic acid.

Abstract: Novel glycosylated steroid derivatives for facilitating the transport of compounds across biological membranes are disclosed. A novel process for efficient synthesis of these glycosylated steroid derivatives, using activated glycosyl sulfoxide intermediates is also provided.

Abstract: The present invention provides a food composition for inhibiting the formation of an intestinal putrefactive product, containing lactosucrose as an effective component. This food composition is low in calorific value because the lactosucrose is indigestible, and can decrease the amount of an putrefactive product to be generated in intestines. Accordingly, this food composition effectively prevents the outbreak of a variety of cancers for which the putrefactive product might serve as a promoter.

Abstract: The invention relates to a pharmaceutical preparation comprising as an active ingredient at least one rhamnolipid or a pharmaceutically acceptable salt thereof, and a carrier and/or diluent, preferably comprising a rhamnolipid of the general formula: ##STR1## wherein R.sub.1 =H, alpha-L-rhamnopyranosyl; ##STR2## R.sub.3 =(C.sub.5 -C.sub.20)-saturated, -mono- of poly-unsaturated alkyl; R.sub.4 =(C.sub.5 -C.sub.

Abstract: Novel water-soluble mono and disaccharides of 1,2-dithiins, as well as methods for their synthesis and the synthesis of 3,6-bis(hydroxymethyl)-1,2-dithiin, are provided. The water-soluble compounds have useful medicinal applications, e.g., as an antifungal agent or antibacterial agent in a pharmaceutically acceptable carrier.

Abstract: The present invention is directed to a novel sustained release matrix and oral dosage form comprising a homogeneous matrix formed from a wet granulation containing an effective amount of a medicament and a polymer blend of hydroxypropyl cellulose and hydroxyethyl cellulose. The present invention also discloses a novel process for making a sustained release oral dosage form comprising wet granulating a medicament with a polymer blend of hydroxypropyl cellulose and hydroxyethyl cellulose to form a homogeneous matrix, wherein the polymer blend is provided in an amount effective to control the release of said medicament, then forming the homogenous matrix into a solid oral dosage form.

Abstract: A composition for the transdermal delivery of a biologically active peptide having a molecular weight of about 5,000 or less comprising at lest one biologically active peptide, at least one higher alcohol, ester and/or higher amide in combination with at least one pyrrolidone compound of the formula: ##STR1## where R.sub.5 is hydrogen or a lower alkyl group having 1 to 4 carbon atoms, R.sub.6 is hydrogen or a lower alkyl group having 1 to 3 carbon atoms and n is 3, 4 or 5. A method for percutaneously administering such a composition is also disclosed.

Abstract: A cosmetic composition comprising an inclusion product having a slightly water-soluble component with a hydroxyalkylated cyclodextrin formulated therein.

Abstract: Disclosed are compositions and methods for prevented or substantially inhibiting the hemolytic activity of hemolysis inducing agents. The methods and compositions are based on the use an anionic oligosaccharide, such as polysulfated cyclodextrin, to achieve the desired reduction in hemolytic active inducing agents.

Abstract: A method of improving the nutritional status and reversing the characteristic diarrhea and inflammatory condition in a mammalian creature having ulcerative colitis or inflammation of the colon which contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.